To minimize fracture incidence, consideration should be given to stopping bisphosphonates (a bisphosphonate holiday) after about 3 to 5 years of use in patients with osteoporosis (by DXA scan) but few or no other risk factors for bone loss (3 years for IV zoledronic acid and 5 years for oral bisphosphonates) 5 to 10 years of use in patients with osteoporosis (by DXA scan) and fractures or additional significant ongoing risk factors for bone loss and future fractures Intermittent cessation of bisphosphonate treatment (drug holiday), as well as initiation and duration of therapy, depend on patient risk factors such as age, comorbidities, prior fracture history, DXA scan results, and fall risk.